SOLICITATION NOTICE
B -- Performing functional screens in Drosophila model systems for 10 genes
- Notice Date
- 6/21/2016
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2016-165-DM
- Archive Date
- 7/12/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a non-competitive sole source basis to the Miami University, P.O. Box 405803, Atlanta, Georgia 30384-5800 to performing functional screens in Drosophila model systems for 10 genes that were expected to be causative in UDP patient disorders. Follow-On Requirement Procurement: • Generating null alleles of candidate genes GEMIN5 and NID2 in Drosophila, and characterizing the null phenotypes in the nervous system; o Establish loss-of-function mutant alleles; o Preliminary analysis of the gross and systemic phenotypes including survival and lifespan (100 flies will be analyzed per allele, 500 to 700 flies per gene); and o Preliminary analysis of the neurological and behavior phenotypes including motor coordination (100 flies will be analyzed per allele, 500 to 700 flies per gene); • Mechanistic analyses of candidate genetic mutations identified in UDP. We propose to analyze one of the following two genes: GEMIN5, and NID2. o Recombine transgenic chromosome with mutant alleles (three-generation genetic crosses to establish 4 to 6 lines per gene; Genotype: (1) UAS-WT;mutant, (2/3) UAS-mut1/2;mutant, (4) UAS-ctrl;mutant); o Cellular analysis of gene expression and protein function; o Detailed rescue analyses, phenotypic comparison with human data; and o Manuscript preparation; • Detailed molecular and cellular mechanistic analysis for GEMIN5 and NID2: o Establish loss-of-function alleles; o Recombine transgenic chromosome with mutant chromosome (three-generation genetic crosses to establish 4 to 6 lines per gene); o Establish global and neuronal specific loss-of-function fly strains; and o Characterize gross and neurological phenotypes of the loss-of-function fly strains. Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. The goals of the UDP include finding accurate diagnoses and discovering new diseases that provide insight into human physiology and genetics. The UDP was established to evaluate participants who have undiagnosed medical conditions. The DIR-NHGRI- Undiagnosed Diseases program (UDP) protocol 76-HG-0238, Clinical Trial Number: NCT00369421 are connected to this testing, which began in 2008 as a vehicle for admitting patients with broader range of inborn errors of metabolism. Under this observational protocol study, the Researchers in the Protocol study intend on diagnosing and treating certain inborn errors of metabolism. By doing this, researchers hope to expand their knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience. Patients enrolled in this protocol have been referred with a known or suspected inborn error of metabolism, heritable disorder, or genetic predisposition. Patients participating in this study will be examined and treated on an outpatient basis, if practical. However, patients requiring specialized tests or treatments will be admitted to the NIH Clinical Center as necessary. Researchers will use only accepted medical procedures in diagnosing (medical history, physical examinations, X-ray studies, eye examinations, blood tests, and urine tests) and treating the patients involved in this study. Additional tests may be required on a case-by-case basis. UDP has a critical need to develop collaborations with Miami University School of Medicine to define the function of genes in causing neurological disease. Purpose and Objectives: The purpose of this acquisition is to provide a screen for genes implicated in neurodevelopmental and neurodegenerative disorders of patients within the Undiagnosed Diseases program. Specifically, this laboratory supports the research needs of the UDP by collaborating on clinically identified new disorders. In the base contract, the University Of Miami Miller School of Medicine was successful in performing functional screens in Drosophila model systems for 10 genes that were expected to be causative in UDP patient disorders. This acquisition is a follow on requirement by the UDP to make transgenic loss of function and null Drosophila models of 2 additional UDP genes and to perform extensive characterization, cellular and molecular analysis of the Drosophila and human homologues of the nervous system to determine if the functional ramifications of the gene mutations corroborate with the phenotype seen in the UDP patients. This will provide functional evidence required to determine if the gene mutation is causative of the patient phenotype. Period of Performance: 12-Months from Date of Award Deliverables: 1. Information on mutant alleles; 2. Information on transgenic lines. 3. Genotype: (1) UAS-WT;mutant, (2/3) UAS-mut1/2;mutant, (4) UAS-ctrl;mutant); 4. Information on loss-of-function alleles. (10 crosses will be set up per allele, 50 to 70 crosses per gene); and 5. Data of phenotypic analyses (sample size: 500 to 700 flies per gene). Regulatory Authority : This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source and is not expected to exceed the simplified acquisition threshold, only one responsible source and no other supplies or services will satisfy agency requirements. This requirement base and option 1 year period is under the SAT of $150,000.00. Statutory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Additional Information: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-88 (May 16, 2016). This requirement is under the Simplified Acquisition Threshold of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received June 27, 2016 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2016-165-DM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2016-165-DM/listing.html)
- Place of Performance
- Address: NIH and Contractor's Location, United States
- Record
- SN04156346-W 20160623/160621234149-90a27d2fd74f0ddf43c44d2340ccf220 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |